Integra LifeSciences Prices $450M Senior Secured Notes at 9.5%

Integra LifeSciences has priced $450 million in senior secured notes due 2033 at a 9.5% interest rate as part of a debt refinancing strategy. The issuance is expected to push the company’s effective interest rate toward the high end of its previously projected 100 to 200 basis-point increase.

The transaction is scheduled to close on or about October 19, 2026, pending the satisfaction of customary closing conditions. By utilizing senior secured notes, the company is using a form of debt that offers specific protections to creditors.

Understanding Senior Secured Notes

Senior secured notes are debt instruments backed by specific company assets, such as equipment, intellectual property, or real estate. This structure provides investors with a higher priority for repayment compared to unsecured bondholders if a company defaults.

Because these notes are collateralized, they are viewed as lower-risk investments than unsecured debt. For the issuer, this security allows for a predictable path to securing capital, though it requires the company to pledge tangible value to back the obligation.

Impact on Capital Structure

According to an 8-K filing submitted by the company, this refinancing effort is a component of its current financial management. The 9.5% coupon rate reflects the current cost of capital for the firm as it restructures its obligations.

The company previously communicated to shareholders that its refinancing activities would result in an interest rate increase of 100 to 200 basis points. With the pricing of these notes, Integra LifeSciences anticipates that its effective interest rate will land near the upper bound of that range, signaling a shift in the firm's long-term interest expense profile.

This move comes as Integra LifeSciences manages its capital structure to balance immediate liquidity needs with long-term debt obligations maturing in 2033. The company has not provided further details on how it intends to allocate the proceeds beyond the stated purpose of refinancing existing debt.